Quotes with Resistance & Support
Market Information

Strides Arcolab receives USFDA approval for 2 more products

This article was posted on Sep 2, 2008 and is filed under Press Releases

Strides Arcolab Limited (“Strides”) today announced receipt of 2 ANDA approvals for Dexamethasone Injection USP, 4mg/ml, (1ml Single-dose Vials, 20mg /5 ml, 120 mg /30 ml Multipledose Vials) and Dexamethasone Sodium Phosphate Injection USP, 10 mg /ml, (10 ml Multiple-dose Vials).

The products are licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE:STAR, BSE: 532531] Ravi Seth, Chief Executive Officer- International Operations of Strides stated: We are pleased to announce that the Akorn Strides partnership has now received eleven ANDA approvals of the 18 filed till date and commercialization in case of some of these products has already commenced effective Q3, 2008.

Tags: , , , ,

Similar Posts:

Breakouts

+ve 30 DMA    50 DMA    150 DMA    200 DMA
-ve 30 DMA    50 DMA    150 DMA    200 DMA

Latest Query

Samrudhiglobal.com wishing you and your friends and family Advance xmas and Happy New year...view more »
- by Sam
Status: Awaiting reply

Market Stats

Search Our Archives

Latest Investment Idea

Recent Comments